trans-3-Methoxy-1-(p-chlorphenyl)-prop-1-en | 22688-02-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: trans-3-Methoxy-1-(p-chlorphenyl)-prop-1-en
• 英文别名: 1-chloro-4-((E)-3-methoxyprop-1-enyl)benzene；(E)-1-(4-chlorophenyl)-3-methoxypropene；1-chloro-4-[(E)-3-methoxyprop-1-enyl]benzene
• CAS: 22688-02-4
• 化学式: C₁₀H₁₁ClO
• 分子量: 182.65
• InChiKey: KSDSQOLSXNFQSC-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  三甲基硅乙酸酯 、 (R)-methyl 2-(2-(diacetoxyiodo)phenoxy)-3-methylbutanoate 、 trans-3-Methoxy-1-(p-chlorphenyl)-prop-1-en 在 三氟化硼乙醚 、 溶剂黄146 、 水 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 以55%的产率得到acetic acid (1R,2S)-2-acetoxy-3-methoxy-1-(4-chlorophenyl)propyl ester
  参考文献：
  名称：

  使用手性高价碘的对映选择性Prevost和Woodward反应（III）：光学活性1,3-二氧杂戊-2-基阳离子的立体化学过程的转换。

  摘要：

  用手性高价碘（III）对烯烃进行对映选择性二氧乙酰化时，生成了旋光的1,3-二氧杂戊-2-基阳离子中间体。亲核试剂对中间体的区域选择性攻击导致二氧乙酰化的对映选择性逆转。

  DOI：

  10.1039/c1cc10129c
• 作为产物：
  描述：

  4-溴氯苯 在 bis-triphenylphosphine-palladium(II) chloride 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 苯 为溶剂， 生成 trans-3-Methoxy-1-(p-chlorphenyl)-prop-1-en
  参考文献：
  名称：

  通过新的甲硅烷基化的有机锡均烯酸酯等效物轻松获得β-酰基和β-芳基-丙醛

  摘要：

  钯催化的新型油溶试剂（α-甲氧基-γ-三丁基锡烷基）烯丙基三甲基硅烷与酰基或芳基卤化物的交叉偶联仅涉及乙烯基-锡键，随后与四丁基氟化铵进行甲硅烷基化反应，制得烯醇醚，即烯醇醚的前体β-酰基或β-芳基丙醛。

  DOI：

  10.1039/c39880000503

文献信息

• MCM-41-supported bidentate phosphine palladium(0) complex as an efficient catalyst for the heterogeneous Stille reaction
  作者：Hong Zhao、Yue Wang、Junchao Sha、Shouri Sheng、Mingzhong Cai

  DOI：10.1016/j.tet.2008.05.120

  日期：2008.8

  Stille coupling reaction of organostannanes with organic halides has been developed in the presence of a catalytic amount of MCM-41-supported bidentate phosphine palladium(0) complex (0.5 mol %) in DMF/H2O (9:1) under air atmosphere in high yields. This polymeric palladium catalyst exhibits higher activity than Pd(PPh3)4 and can be reused at least 10 times without any decrease in activity.

  在空气中DMF / H 2 O（9：1）中催化量的MCM-41负载的双齿膦膦钯（0）络合物（0.5 mol％）的存在下，开发了有机锡与有机卤化物的Stille偶联反应。高产的气氛。该聚合钯催化剂显示出比Pd（PPh 3）4更高的活性，并且可以重复使用至少10次而活性没有降低。
• Asymmetric Allylic Alkylation of Acyclic Allylic Ethers with Organolithium Reagents
  作者：Manuel Pérez、Martín Fañanás-Mastral、Valentín Hornillos、Alena Rudolph、Pieter H. Bos、Syuzanna R. Harutyunyan、Ben L. Feringa

  DOI：10.1002/chem.201202251

  日期：2012.9.17

  CuI/phosphoramidite‐catalyzed asymmetric allylic alkylation of allyl ethers with organolithium reagents is reported (see scheme). The use of organolithium reagents is essential for this catalytic CC bond formation due to their compatibility with different Lewis acids. The versatility of allylic ethers under the copper‐catalyzed reaction conditions with organolithium reagents is demonstrated in the shortest

  报道了用有机锂试剂对烯丙基醚进行的高效，区域和对映选择性的Cu I /亚磷酰胺催化的不对称烯丙基烷基化反应（参见方案）。由于与不同的路易斯酸具有相容性，因此使用有机锂试剂对于这种催化的CC键形成至关重要。（S）-戊二酸的最短合成证明了烯丙基醚在铜催化的条件下与有机锂试剂的多功能性。
• An easy access to β-acyl- and β-aryl-propionaldehydes through a new silylated organotin homoenolate equivalent
  作者：Jean-Baptiste Verlhac、Jean-Paul Quintard、Michel Pereyre

  DOI：10.1039/c39880000503

  日期：——

  Palladium-catalysed cross-coupling of a new umpolung reagent, (α-methoxy-γ-tributylstannyl)allyltrimethyl-silane, with acyl or aryl halides, involves exclusively the vinyl–tin bond and subsequent desilylation with tetrabutylammonium fluoride gives enol ethers, precursors of β-acyl- or β-aryl-propionaldehydes.

  钯催化的新型油溶试剂（α-甲氧基-γ-三丁基锡烷基）烯丙基三甲基硅烷与酰基或芳基卤化物的交叉偶联仅涉及乙烯基-锡键，随后与四丁基氟化铵进行甲硅烷基化反应，制得烯醇醚，即烯醇醚的前体β-酰基或β-芳基丙醛。
• (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS
  申请人：Iwema Bakker Wouter I.

  公开号：US20120220552A1

  公开（公告）日：2012-08-30

  The present disclosure relates to (thio)morpholine derivatives of the formula (I) wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino, —SO 2 -(1-4C)alkyl, —CO-(1-4C)alkyl, —CO—O-(1-4C)alkyl, —NH—CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from —CO—O—, —O—CO—, —NH—CO—, —CO—NH, —C═C—, —CCH 3 —O— and the linking group —Y—(CH 2 ) n —X— wherein Y is attached to R1 and selected from a bond, —O—, —S—, —SO—, —SO 2 —, —CH 2 —O—, —CO—, —O—CO—, —CO—O—, —CO—NH—, —NH—CO—, —C═C— and —C≡C—; n is an integer from 1 to 10; and X is attached to the phenylene/pyridyl group and selected from a bond, —O—, —S—, —SO—, —SO 2 —, —NH, —CO—, —C═C— and —C≡C—; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH 2 ) 2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is (3-6C)cycloalkylene-R5 or —CO—CH 2 —R5, wherein R5 is —OH, —PO 3 H 2 , —OPO 3 H 2 , —COOH, —COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is —O—, —S—, —SO— or —SO 2 —; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the disclosure have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

  本公开涉及以下式子的(硫)吗啡啶衍生物(I)： 其中，R1从氰基，(2-4C)炔基，(1-4C)烷基，(3-6C)环烷基，(4-6C)环烯基，(6-8C)双环烷基，(8-10C)双环基中选择，每个基都可以选择性地被(1-4C)烷基，苯基，联苯基，萘基取代，每个基也可以选择性地被一个或多个取代基独立地选择，所述取代基包括卤素，(1-4C)烷基可选择地被一个或多个氟原子取代，(2-4C)炔基，(1-4C)烷氧基可选择性地被一个或多个氟原子取代，氨基，二(1-4C)烷基氨基，—SO2-(1-4C)烷基，—CO-(1-4C)烷基，—CO—O-(1-4C)烷基，—NH—CO-(1-4C)烷基和(3-6C)环烷基，苯基取代为苯氧基，苄基，苄氧基，苯乙基或单环杂环，每个基都可以选择性地被(1-4C)烷基取代，单环杂环可选择性地被卤素，(1-4C)烷基或苯基取代，或双环杂环可选择性地被(1-4C)烷基取代； A从—CO—O—，—O—CO—，—NH—CO—，—CO—NH，—C═C—，—CCH3—O—和连接基—Y—(CH2)n—X—中选择，其中Y连接到R1并从键，—O—，—S—，—SO—，—SO2—，—CH2—O—，—CO—，—O—CO—，—CO—O—，—CO—NH—，—NH—CO—，—C═C—和—C≡C—中选择；n是1到10的整数；X连接到苯基/吡啶基并从键，—O—，—S—，—SO—，—SO2—，—NH，—CO—，—C═C—和—C≡C—中选择；环结构B可选择性地包含一个氮原子； R2为H，(1-4C)烷基可选择性地被一个或多个氟原子取代，(1-4C)烷氧基可选择性地被一个或多个氟原子取代，或卤素； R3为(1-4C)烷基-R5，其中烷基可以被(CH2)2取代以形成环丙基基团或一或两个卤素原子，或R3为(3-6C)环烷基-R5或—CO—CH2—R5，其中R5为—OH，—PO3H2，—OPO3H2，—COOH，—COO(1-4C)烷基或四唑-5-基； R4为H或(1-4C)烷基； R6为一个或多个取代基，独立地选择自H，(1-4C)烷基或氧代基； W为—O—，—S—，—SO—或—SO2—； 或其药学上可接受的盐、溶剂或水合物； 但是，公开的衍生物式(I)不包括2-(4-乙基苯基)-4-吗啡啶基乙醇或4-[4-(2-羟乙基)-2-吗啡啶基]苯乙腈或其药学上可接受的盐、溶剂或水合物。 本公开的化合物具有对S1P受体的亲和力，并可用于治疗、缓解或预防S1P受体介导的疾病和症状。
• Partition of unsaturated diazotates between diazoalkenes and carbonium ions in base
  作者：Harold Hart、James L. Brewbaker

  DOI：10.1021/ja01031a035

  日期：1969.1